NCT01068925View on ClinicalTrials.gov

Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 15, 2010

Primary Completion Date

April 5, 2010

Study Completion Date

April 5, 2010

Conditions
Infection, Human Immunodeficiency VirusHIV Infections
Interventions
DRUG

GSK1349572

"1. GSK1349572 QD x 5 days~2. TPV/RTV 500/200mg BID x 7 days~3. GSK1349572 50mg QD and TPV/RTV 500/200mg BID x 5 days"

Trial Locations (1)

78744

GSK Investigational Site, Austin

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (2)

Shionogi
GlaxoSmithKline
All Listed Sponsors
collaborator

Shionogi

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY

NCT01068925 - Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers | Biotech Hunter | Biotech Hunter